European Psychiatry - Volume 33 - March 2016

683 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805 S679
be associated with an elevated frequency of metabolic alterations
causing an important weight disorder and glucose and lipid home-
ostasis, diminishing life expectations for these patients, likely to
develop metabolic syndrome without proper control.
Objectives This study intended to find the association between
metabolic syndrome in patients with psychotropic treatments used
in the Guatemalan Institute of Social Security (IGSS).
Methodology Cohort Study (n = 43 patients) who were treated
combined with antipsychotics and mood stabilizers or antidepres-
sants, conducting checkups at the beginning, then two to four
months after, evaluating diagnosis of metabolic syndrome accord-
ing to the criteria stated by the International Diabetes Federation
(IDF).
Results Risk factorwith the use of clozapine and valproic acidwas
revealed after four months of exposure (RR = 2.32). With the use of
clozapine and mood stabilizers a risk factor was prevalent with
exposure after four months (RR = 2.67), and with the use of antide-
pressants a protective factor for the development of metabolic
syndrome was revealed at four months of exposure (RR = 0.3741).
Conclusions the use of antipsychotics in combination with mood
stabilizers represents a risk factor for developing metabolic syn-
drome, especially the association with valproic acid.
Keywords Metabolic syndrome; Clozapine; Stabilizers;
Antidepressants
Disclosure of interest The author has not supplied his declaration
of competing interest.
EV1032
Antipsychotics-induced leukopenia
and neutropenia: A case report and
review of literature
H. Maatallah∗, H. Ben Ammar , M. Said , A. Aissa
Razi Hospital, Tunis, Tunisia
∗ Corresponding author.
Introduction Antipsychotic drugs effectively control psychotic
symptoms, but may cause important side effects, significantly
increasing morbidity and mortality. Hematologic abnormalities
are frequent and may be life-threatening in some patients. Many
prospective investigations confirmed neutropenia as a frequent
occurrence with virtually all atypical antipsychotics.
Objective and methods Define epidemiological, clinical and ther-
apeutic characteristics of antipsychotics – induced leukopenia and
neutropenia through a case report and a review of literature.
Case report Patient 28 years old native of Tunis, with fam-
ily history: brother who suffer of undifferentiated schizophrenia.
Since the age of 16 years he has been followed for disorga-
nized schizophrenia (DSM IV). He was initially put under Haldol
Decanoate (2 months), fluphenazine (2 months), amisulpride (3
months), sulpride (2 months), olanzapine (3 months), Rispreri-
done (1 month), aripiprazole (5 months) leukopenia/neutropenia
is occurring during treatment with each molecule and which
promptly resolved after discontinuation. Reduced white blood cell
count has also been reported after addition of lithium. Actually an
ECT is proposed for this patient.
Conclusion This case report shows the importance of hematolog-
ical monitoring during the course of typical or atypical treatment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1033
Sociodemographic variables and
efficacy study in psychotic patients
after 12 months of outpatient
treatment with paliperidone
palmitate (PP)
P. Manzur Rojas∗, P. Botias Cegarra , M.R. Raposo Hernandez ,
M.I. Ibernon Caballero , A. Sanchez Bahillo ,
A.L. Gonzalez Galdamez , M.J. Martinez Mirete , A. Belmar Simo ,
M.A. Carrillo Cordoba
Centro de Salud Mental de Cartagena, Psiquiatria, Cartagena, Spain
∗ Corresponding author.
Introduction Psychotic disorders are seriousmental illnesses that
compromise the quality of life of patients. It is important to know
the characteristics of the affected population, seek to improve the
adhesion and functionality.
Objectives To describe the sociodemographic characteristics of
patients treated with Palmitato Paliperidona (PP). Analyze the effi-
cacy variables, adherence to treatment.
Methods Cross-sectional study of 15 patients in outpatient
follow-up after 12 months of treatment with PP. Sociodemographic
characteristics are collected, mean dose of PP, through a mir-
ror study. Scales to measure the functionality, clinical status and
attitude towards medication apply: Scale of personal and social
functioning (PSP), Brief Psychiatric Rating Scale (BPRS), Clinical
Global Impression Scale (CGI-SI) and attitudes toward Inventory
Medication (DAI).
Results The sample consists of 15 patients (54% male). 81% are
single; 77% live alone and 94% not working. The mean dose of PP is
147mg/month. DAI shows a good attitude to the treatment (80%).
The PSP shows that 22% of patients have serious difficulties in its
development. The CGI-SI shows that 67% are moderately sick and
the BPRS that 33% of patients have a serious disorder.
Conclusions The demographic profile of patients after 12 months
of treatment with PP coincides withmale, unmarried, unemployed,
living alone. Most have good adherence. The variables measured
by the CGI-SI, BPRS and PSP, displayed moderately ill patients with
severe difficulties or marked on their autonomy.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1034
About existence of overmedication in
patients with depressive symptoms
and the appearance of un-induced
movement disorder
P. Manzur Rojas∗, M.A. Carrillo Cordoba , A. Sanchez Bahillo ,
M.R. Raposo Hernandez , P. Botias Cegarra , M.I. Ibernon Caballero
Centro de Salud Mental de Cartagena, Psiquiatria, Cartagena, Spain
∗ Corresponding author.
Overmedication and the combined use of various antidepressants
while increasingly seen in daily clinical practice. The drug-induced
Parkinsonism, often presented as tremor, rigidity, bradykinesia
and impaired postural reflexes. The syndrome is caused by mul-
tiple drug drugs can be classified into high risk, intermediate and
low. This case is a 75-year-old woman diagnosed with recurrent
depressive disorder, which after several adjustments in medica-
tion for depressive symptoms with poor response to treatment.
It is referred by her family doctor to the neurologist at the
onset of tremors in limbs, dyskinesia orolinguales, rigidity and
bradykinesia. After studies to rule out organic neurology disease, is
derived psychiatry for changing inducing drugs parkinsonism. The
last scheduled treatment was: Mirtazapine 15mg/day, quetiapine
25mg/day, Clonazepam 2mg/day, paroxetine 40mg/day, Sulpiride